FEIBA


Also found in: Medical.
AcronymDefinition
FEIBAFactor Eight Inhibitor Bypassing Activity (freeze-dried, sterile, human plasma fraction used to aid in coagulation)
References in periodicals archive ?
Lauroua, Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors.
The current guidelines recommend the use of FEIBA (activated PCC) for reversal of factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban) only when the PCC fails, as activated PCC was not found to be superior to PCC for this indication, and carries a higher risk of thrombotic complications than regular PCC [27].
Hemostatic management of surgical procedures with Feiba: a Turkish case series.
None of the factors are activated, as opposed to FEIBA. (1,5,6) It is notable that Kcentra has a higher reported range of concentration of protein C than other 4F-PCCs, which suggests a theoretical "balanced" safety profile compared to other concentrates, but this has not been proven in any study known to these authors.
FEIBA actua en su mayor parte a nivel del complejo protrombinasa convirtiendo protrombina a trombina por medio del FXa a nivel de la superficie de fosfolipidos, mien tras el rFVIIa activa al FX en las plaquetas activadas restaurando suficiente trombina para generar un coagulo estable (5, 6).
Other agents specifically used for bleeding episodes are FEIBA (factor VIII inhibitor bypassing activity containing activated factors VII, IX or X) or recombinant activated factor VII (3).
[45] Baxter Healthcare Corporation, "Thrombotic and thromboembolic events following infusion of FEIBA VH or FEIBA NF," 2010, http://www.fda.gov/downloads/ biologicsbloodvaccines/safetyavailability/ucm221755.pdf.
It was reported on Friday that Baxter International, a United States-based healthcare company, has received approval for its FEIBA (Anti-Inhibitor Coagulant Complex) from the US Food and Drug Administration.
Treatment of bleeding episodes occurring in patients with acquired haemophilia with FEIBA: the French experience.
Yaygin intraabdominal kanamasi olan inhibitor gelismis hemofili A hastasinda FEIBA kullanimi.
The 2 percent hike in plasma protein sales was driven by strong international demand for Feiba as well as anti-inhibitor coagulant complex, and improved domestic sales of Aralast NP (Alpha 1-Proteinase Inhibitor [Human]).